Macquarie Group Ltd. lowered its stake in Icon Plc (NASDAQ:ICLR) by 2.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 487,159 shares of the medical research company’s stock after selling 14,505 shares during the period. Macquarie Group Ltd. owned 0.89% of Icon Plc worth $36,634,000 at the end of the most recent quarter.
Other large investors have also bought and sold shares of the company. US Bancorp DE increased its stake in Icon Plc by 4.0% in the third quarter. US Bancorp DE now owns 1,650 shares of the medical research company’s stock valued at $128,000 after buying an additional 64 shares in the last quarter. 1st Global Advisors Inc. increased its position in shares of Icon Plc by 2.6% in the third quarter. 1st Global Advisors Inc. now owns 4,932 shares of the medical research company’s stock worth $382,000 after buying an additional 124 shares during the period. Greenwood Capital Associates LLC increased its position in shares of Icon Plc by 4.8% in the fourth quarter. Greenwood Capital Associates LLC now owns 3,462 shares of the medical research company’s stock worth $260,000 after buying an additional 158 shares during the period. Groesbeck Investment Management Corp NJ increased its position in shares of Icon Plc by 7.6% in the third quarter. Groesbeck Investment Management Corp NJ now owns 3,821 shares of the medical research company’s stock worth $296,000 after buying an additional 271 shares during the period. Finally, FineMark National Bank & Trust increased its position in shares of Icon Plc by 24.8% in the third quarter. FineMark National Bank & Trust now owns 1,469 shares of the medical research company’s stock worth $114,000 after buying an additional 292 shares during the period. Institutional investors and hedge funds own 88.14% of the company’s stock.
Icon Plc (NASDAQ:ICLR) traded up 0.117% during mid-day trading on Friday, hitting $80.244. 92,037 shares of the stock traded hands. Icon Plc has a 1-year low of $62.31 and a 1-year high of $88.90. The firm has a market capitalization of $4.38 billion, a P/E ratio of 17.257 and a beta of 0.63. The company has a 50-day moving average of $79.82 and a 200 day moving average of $79.70.
Icon Plc (NASDAQ:ICLR) last posted its quarterly earnings data on Thursday, February 16th. The medical research company reported $1.33 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.26 by $0.07. The business earned $435 million during the quarter, compared to the consensus estimate of $440.78 million. Icon Plc had a return on equity of 29.47% and a net margin of 15.60%. The firm’s quarterly revenue was up 7.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.11 earnings per share. On average, equities research analysts anticipate that Icon Plc will post $5.12 EPS for the current year.
ILLEGAL ACTIVITY WARNING: This piece was posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be read at https://www.chaffeybreeze.com/2017/04/21/icon-plc-iclr-stake-cut-by-macquarie-group-ltd-updated.html.
A number of brokerages have recently issued reports on ICLR. Jefferies Group LLC restated a “hold” rating and issued a $84.00 price target (down previously from $87.50) on shares of Icon Plc in a research report on Friday, January 6th. Zacks Investment Research downgraded shares of Icon Plc from a “hold” rating to a “sell” rating in a research report on Tuesday, December 27th. Finally, Mizuho began coverage on shares of Icon Plc in a research report on Thursday, March 23rd. They issued a “neutral” rating and a $66.00 price target on the stock. Five analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Icon Plc has a consensus rating of “Buy” and a consensus target price of $80.50.
Icon Plc Company Profile
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
Receive News & Ratings for Icon Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon Plc and related companies with MarketBeat.com's FREE daily email newsletter.